TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05759923: An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours (Colore

Sponsor: Molecure S.A. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,581,424

Rescue Site Savings

+$2,356,200

Unlock Full NCT05759923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05759923 Rescue Dossier →